Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 6/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295128 | 0.92 | HTT (0.46) | FFAR1MMP12MMP13 | |
| SCHEMBL10798983 | 0.85 | BCHE (0.50) | LTA4HSLC2A1BCHE | |
| SCHEMBL18714850 | 0.84 | FDFT1 (0.53) | FFAR1FDFT1 | |
| SCHEMBL11420676 | 0.82 | MMP12 (0.48) | FFAR1MMP12MMP13LTA4HSLC2A1 | |
| SCHEMBL167715 | 0.81 | AOC3 (0.55) | TSHR | |
| SCHEMBL19322270 | 0.81 | LTA4H (0.67) | FFAR1MMP12MMP13LTA4HTSHR | |
| Benzene SCHEMBL27914804 | 0.81 | AOC3 (0.55) | TSHR | |
| SCHEMBL10085324 | 0.80 | BCHE (0.68) | FFAR1MMP12LTA4HBCHEFFAR4 | |
| SCHEMBL9252743 | 0.80 | LTA4H (0.55) | FFAR1LTA4HSLC2A1TSHR | |
| Ammonia Solution, Strong SCHEMBL4461727 | 0.79 | AOC3 (0.53) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | REDHILL BIOPHARMA LTD. (IL) | 2023-10-17 | — | — | US | disclosed |
| US-11633385-B2 | Combination compositions for treatment of cancer | REDHILL BIOPHARMA LTD. (IL) | 2023-04-25 | — | — | US | disclosed |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | REDHILL BIOPHARMA LTD (IL) | 2021-12-02 | — | — | US | disclosed |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | REDHILL BIOPHARMA LTD (IL) | 2021-05-06 | — | — | US | disclosed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2020-01-28 | — | — | US | disclosed |
| US-10463654-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2019-11-05 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-9974800-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2018-05-22 | — | — | US | disclosed |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD (IL) | 2018-05-10 | — | — | US | disclosed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | RNMT, EIF2AK2, POLRMT | FFAR1 3198/4885MMP12 2849/4885MMP13 2587/4885 |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | FFAR1 4298/4885MMP12 4481/4885MMP13 4238/4885 |
| US-20180125831-A1 | COMBINATION THERAPIES FOR TREATING CANCER | TPMT, KRAS, ACE | FFAR1 3395/4885MMP12 276/4885MMP13 3525/4885 |
| US-11786541-B2 | Inhibitor of sphingosine kinase 2 for treating Ebola | SPHK2, SPHK1, S1PR2 | FFAR1 1495/4885MMP12 2992/4885MMP13 4318/4885 |
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | FFAR1 3415/4885MMP12 562/4885MMP13 3948/4885 |
| US-11633385-B2 | Combination compositions for treatment of cancer | KRAS, TPMT, CYP2D6 | FFAR1 3328/4885MMP12 675/4885MMP13 4150/4885 |
| US-20210128538-A1 | COMBINATION COMPOSITIONS FOR TREATMENT OF CANCER | KRAS, TPMT, CYP2D6 | FFAR1 3328/4885MMP12 675/4885MMP13 4150/4885 |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | FFAR1 4298/4885MMP12 4481/4885MMP13 4238/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | FFAR1 3354/4885MMP12 706/4885MMP13 3452/4885 |
| US-20210369754-A1 | INHIBITOR OF SPHINGOSINE KINASE 2 FOR TREATING EBOLA | SPHK2, SPHK1, S1PR2 | FFAR1 1495/4885MMP12 2992/4885MMP13 4318/4885 |
| US-10463654-B2 | Combination therapies for treating cancer | TPMT, KRAS, ACE | FFAR1 3395/4885MMP12 276/4885MMP13 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.